We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Silicon Treatment Preserves Antibiotics and Vaccines for Years

By LabMedica International staff writers
Posted on 03 May 2017
Print article
Image: A sample of silicon dioxide (Photo courtesy of Wikimedia Commons).
Image: A sample of silicon dioxide (Photo courtesy of Wikimedia Commons).
A novel method for encasing molecules of biomedical interest such as antibodies and vaccines in silica "cages" stabilizes them against denaturing thermal treatment and long-term ambient-temperature storage, and subsequently enables them to be released into solution with their structure and function intact.

Biological substances based on proteins, including vaccines, antibodies, and enzymes, typically degrade at room temperature over time due to denaturation, as proteins unfold with loss of secondary and tertiary structure. Their storage and distribution therefore relies on a "cold chain" of continuous refrigeration, which is costly and not always effective, as any break in the chain leads to rapid loss of effectiveness and potency. Efforts have been made to make vaccines thermally stable using treatments including freeze-drying (lyophilization), biomineralization, and encapsulation in sugar glass and organic polymers.

In a new approach, investigators at the University of Bath and colleagues at the University of Newcastle used a silica-based process to stabilize protein structure. In this process, a protein in solution was mixed with silicon dioxide, which bound closely around the protein to match its shape, and quickly built up many layers, encasing the protein. This method did not require freeze-drying, a treatment that potential destroys half of all vaccines.

The investigators reported in the April 24, 2017, online edition of the journal Scientific Reports that they had used this "ensilication" process to treat hen egg white lysozyme (HEWL), a robust and well-characterized protein with enzymatic activity; horse hemoglobin, a heterotetrameric protein with a complex tertiary and quaternary structure; and tetanus toxin C-fragment (TTCF)22, a vaccinogenic tetanus fragment, which is a part of the commonly used DTP vaccine. Results revealed that the proteins could be heated to 100 degrees Celsius or stored at 22 degrees Celsius for at least six months with no loss of function.

Senior author Dr. Asel Sartbaeva, a research fellow in chemistry at the University of Bath, said, "We have demonstrated with ensilication that we can simply and reliably keep proteins from breaking down even at up to 100°C, or store them as a powder for up to three years at room temperature without loss of function. We are very excited by the potential applications of ensilication and our next steps will be to test our findings on more vaccines, antibodies, antiviral and anti-venom drugs, and other biopharmaceuticals."

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease (Photo courtesy of 123RF)

Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease

Cerebral small vessel disease is a common cause of stroke and cognitive decline, particularly in the elderly. Presently, assessing the risk for cerebral vascular diseases involves using a mix of diagnostic... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.